Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
NCT07220252Phase 2/3Recruiting
- Lead sponsor
- TG Therapeutics, Inc. (Industry)
- Enrollment
- 240 (estimated)
- Start date
- 1 Jul 2026
- Primary completion
- 1 Jan 2030 (estimated)
- Study completion
- 30 Jun 2033
- Last update posted
- 29 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 6
Interventions
- Ublituximab Drug
- Placebo Drug
- Fingolimod Drug
Conditions and primary outcome
- Relapsing Multiple Sclerosis
Primary outcome
Part A: Area Under the Curve From Week 0 to 24 (AUC0-W24) of Ublituximab (Predose and multiple timepoints up to Week 24); Part A: Maximum Observed Concentration (Cmax) of Ublituximab (Day 1 and Day 15); Part A: Participant B Cell Counts (Up to Week 24); Part B: Annualized Relapse Rate (ARR) (Up to 96 weeks); Part C: Annualized Relapse Rate (ARR) (Up to 168 weeks)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07220252.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07220252 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.